Compare Pinterest Inc (PINS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pinterest Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Pinterest Inc trades at $22.54 (market cap $12.79B), while Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 5.5× Pinterest Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Pinterest Inc pays none. Which is the better fit depends on your goals.
| PINS | REGN | |
|---|---|---|
Market Cap | $12.79B | $70.79B |
Sector | Media | Health |
52-Week High | $39.17 | $812.27 |
52-Week Low | $15.42 | $545.46 |
Enterprise Value | $12.69B | $64.74B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pinterest (PINS) trades at $22.835, down 1.57% on the day, with a bullish technical outlook driven by moving averages and a consensus analyst price target of $27.53. Revenue grew to $4.22B in 2025, with net income turning positive at $416.86M, though Q2 2026 earnings are pending. Recent news highlights focus on user growth and e-commerce integration, while insider sales and cash flow trends warrant monitoring.
The stock presents upside potential from strong analyst buy ratings and revenue expansion, but risks include negative net cash flow, high valuation multiples, and competitive pressures in social media. Investor sentiment is cautiously optimistic ahead of Q2 earnings, with institutional activity showing mixed signals.
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pinterest Inc
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
